SGMT sagimet.com Net earnings per share for the last 12 months

Public company logo of Sagimet Biosciences (SGMT)

The rolling 12-month EPS trend for Sagimet Biosciences (SGMT) is supported by the development of a mass-market NASH therapy. The business foundation relies on strict FDA oversight and patent protection for FASN inhibitors. The potential for monopoly pricing power within the MASH niche ensures future growth. Currently, the metric stands at -1.19, allowing institutional investors to assess capital efficiency.

SGMT (Sagimet Biosciences Inc) Net earnings per share (EPS TTM) history from 02/21/2024 to 11/18/2026

Analytical breakdowns and data insights for company Sagimet Biosciences Inc (SGMT)

Fundamental company valuation:Sagimet Biosciences, Inc. (SGMT)
Mass-produced product of Sagimet

To objectively value an asset, an investor must compare market value with actual capital accumulation, which allows for the identification of an undervalued security via the fundamental TTM earnings per share metric. This metric allocates the total annual financial result to a single common share, demonstrating the monetization efficiency of Sagimet Biosciences patents and the potential for excess profits when scaling the production of liver medications.

Competitors of Sagimet Biosciences

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS